Objective To observe the efficacy of elosumab combined with conventional statins and simple statin fortification in patients with acute coronary syndrome(ACS) and the effect on the expression of high mobility group protein B1(HMGB1), amyloid protein A1(SAA1), and CC chemokine 19(CCL19) in serum. Methods From January 2021 to January 2022, 92 patients with ACS admitted to the Department of Cardiology in the North of Shanghai Ninth People's Hospital were randomly divided into a control group of 46 patients and a combined group of 46 patients. The control group was treated with simple statin intensive therapy, while the combined group was treated with elosumab combined with conventional statin therapy. Compare the efficacy and adverse reaction rates of the two groups, as well as the serum levels of HMGB1, SAA1, CCL19, and blood lipids before and after treatment. Results After 6 months of treatment, the total effective rate of the combination group was higher than that of the control group(93.48% vs. 78.26%,χ²/P=4.389/0.036); after 6 months of treatment, the serum levels of HMGB1, SAA1, and CCL19 in both groups were lower than before treatment, and the combination group was lower than the control group(t/P=6.252/<0.001, 6.225/<0.001, 4.740/<0.001); after 6 months of treatment, the serum levels of total cholesterol(TC), triglycerides(TG), and low-density lipoprotein cholesterol(LDL-C) in both groups were lower than before treatment, and high-density lipoprotein cholesterol(HDL-C) was higher than before treatment, and the reduction/increase amplitude of the combination group was greater than that of the control group(t/P=10.281/<0.001, 7.619/<0.001, 4.740/<0.001, 2.801/0.040); the incidence of adverse reactions in the combination group was lower than that in the control group(χ²/P=4.246/0.039). Conclusion The efficacy of elosumab combined with conventional statins in patients with ACS is superior to that of simple statin fortification. It can effectively reduce blood lipids, alleviate inflammatory reactions, and reduce the expression levels of serum HMGB1, SAA1, and CCL19, with high safety.

Acute coronary syndrome;                    Elotuzumab;                    Atorvastatin;                    High mobility group protein B1;                    Amyloid A1;                    CC chemokine 19;